NCT06394713View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

June 15, 2025

Study Completion Date

December 15, 2026

Conditions
Advanced Malignant Neoplasm
Interventions
DRUG

QLF31907

intravenous administration, once every 3 weeks

DRUG

Irinotecan

intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks

DRUG

Docetaxel

intravenous administration, 75mg/m2, d1, every 3 weeks

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06394713 - A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter